Targeted Approaches to T-Cell Lymphoma

被引:1
|
作者
Harrop, Sean [1 ]
Abeyakoon, Chathuri [2 ]
Van der Weyden, Carrie [1 ]
Prince, H. Miles [1 ,3 ,4 ]
机构
[1] Peter MacCallum Canc Ctr, Melbourne, Vic 3000, Australia
[2] Monash Hlth, Melbourne, Vic 3168, Australia
[3] Epworth Healthcare, Melbourne, Vic 3002, Australia
[4] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic 3000, Australia
来源
JOURNAL OF PERSONALIZED MEDICINE | 2021年 / 11卷 / 06期
关键词
novel agents; monoclonal antibodies; immunotherapy; NON-HODGKIN-LYMPHOMA; BRENTUXIMAB VEDOTIN; PHASE-II; MYCOSIS-FUNGOIDES; OPEN-LABEL; CD30; EXPRESSION; SEZARY-SYNDROME; PI3K-DELTA; GAMMA INHIBITOR; MONOCLONAL-ANTIBODY; PHYSICIANS CHOICE;
D O I
10.3390/jpm11060481
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
The T-cell lymphomas are a rare group of Non-Hodgkin's lymphomas derived from mature T-lymphocytes. They are divided broadly into the Peripheral T-cell lymphomas and the Cutaneous T-cell lymphomas. Clinical outcomes vary widely but are generally unsatisfactory with current treatments. The development of an understanding of the various critical pathways in T-cell lymphogenesis and subsequent identification of therapeutic targets has led to a rapid expansion of the previously underwhelming T-cell lymphoma armament. This review aims to provide an up-to-date overview of the current state of targeted therapies in the T-cell lymphomas, including novel antibody-based treatments, small molecule inhibitors and immune-based therapies.
引用
收藏
页数:16
相关论文
共 50 条
  • [41] Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma
    Zinzani, Pier Luigi
    Salles, Gilles
    Moskowitz, Alison J.
    Santoro, Armando
    Mehta, Amitkumar
    Barr, Paul M.
    Mehta-Shah, Neha
    Collins, Graham P.
    Ansell, Stephen M.
    Brody, Joshua D.
    Domingo-Domenech, Eva
    Johnson, Nathalie A.
    Cunningham, David
    Ferrari, Silvia
    Lisano, Julie
    Krajewski, Jennifer
    Wen, Rachael
    Akyol, Alev
    Crowe, Russell
    Savage, Kerry J.
    BLOOD ADVANCES, 2024, 8 (10) : 2400 - 2404
  • [42] Chimeric Antigen Receptors for T-Cell Malignancies
    Scherer, Lauren D.
    Brenner, Malcolm K.
    Mamonkin, Maksim
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [43] Advances in Novel Systemic Therapies for the Management of Cutaneous T Cell Lymphoma (CTCL)
    Case, Katherine B.
    Allen, Pamela B.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2025, 20 (01)
  • [44] Cutaneous T-Cell Lymphoma: Roles for Chemokines and Chemokine Receptors
    Wu, Xue-Song
    Lonsdorf, Anke S.
    Hwang, Sam T.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2009, 129 (05) : 1115 - 1119
  • [45] Epigenetics of cutaneous T-cell lymphoma: biomarkers and therapeutic potentials
    Lai, Pan
    Wang, Yang
    CANCER BIOLOGY & MEDICINE, 2021, 18 (01) : 34 - 51
  • [46] Characterizing Outcomes in Visceral Cutaneous T-Cell Lymphoma: A Single Center Retrospective Study
    Zhuang, Tony Zibo
    McCook-Veal, Ashley
    Switchenko, Jeffrey
    Niyogusaba, Tim
    Tarabadkar, Erica S.
    Baird, Katelin
    O'Leary, Colin
    Paulino, Darina
    Lechowicz, Mary Jo
    Allen, Pamela B.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (09) : 667 - 673
  • [47] New Approaches for Treatment of Advanced Extranodal NK/T-Cell Lymphoma
    Yi, Wu
    Yang, Tianxin
    Lin, Sisi
    Hao, Rui
    Yu, Jin
    Wang, Ying
    Tong, Xiangming
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 401 - 407
  • [48] Recent Advances in Therapeutic Approaches for Adult T-cell Leukemia/Lymphoma
    Kato, Koji
    Akashi, Koichi
    VIRUSES-BASEL, 2015, 7 (12): : 6604 - 6612
  • [49] Safety considerations with the current treatments for peripheral T-cell lymphoma
    Sethi, Tarsheen
    Montanari, Francesca
    Foss, Francine
    EXPERT OPINION ON DRUG SAFETY, 2022, 21 (05) : 653 - 660
  • [50] Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma
    Lunning, Matthew A.
    Vose, Julie M.
    BLOOD, 2017, 129 (09) : 1095 - 1102